GENE ONLINE|News &
Opinion
Blog

Trials & Approvals
AstraZeneca’s Imfinzi, Tremelimumab Combo Significantly Improves Overall Survival in Phase 3 Trials
2021-10-18
Eli Lilly’s Early Breast Cancer Drug Gets FDA Nod but Faces Tricky Rollout
2021-10-14
Takeda Hits the Brakes on Narcolepsy Drug Trials
2021-10-07
Kyowa Kirin, Amgen’s Atopic Dermatitis Drug Delivers Strong Results in Phase 2 Trial
2021-10-05
FDA Greenlights First and Only Treatment for Cholestatic Pruritus with ALGS
2021-10-04
FDA Approves Kite’s CAR-T Therapy for Adult Leukemia
2021-10-04
Decreasing Earnings and COVID Delays Spell Trouble for AGCT
2021-09-26
AZ, Merck’s PARP Inhibitor Shines in Phase 3 Prostate Cancer Trial
2021-09-26
FDA Approves Incyte’s Jakafi for Chronic Graft-Versus-Host Disease
2021-09-23
Seagen, Genmab’s Antibody Drug Conjugate Bags FDA Approval for Cervical Cancer
2021-09-22
COVID-19: Pfizer/BioNTech Say Their Vaccine is Safe and Protective in 5- to 11-Year-Olds
2021-09-20
Biogen Reports Positive Results for Non-Opioid Oral Pain Drug
2021-09-19
FDA Accepts BeiGene’s BLA for Esophageal Cancer Drug
2021-09-14
Wave Initiates Trial of Investigational Antisense Oligonucleotide Against Huntington’s Disease
2021-09-13
NHS to Roll Out Revolutionary Lung Cancer Drug Targeting the Once ‘Undruggable’ KRAS
2021-09-12
1 24 25 26 27 28 50
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top